Media ReleasesNoxopharm

View All Noxopharm News


Noxopharm Announces COVID-19 Trial Program to Commence in Europe


NOX announces commencement of its NOXCOVID clinical program with a planned Phase 1 trial in Europe. This action is designed to provide important safety data and proof-of-principle of Veyonda as a potential treatment of septic shock before committing the Company to a major study.

Noxopharm is progressing its NOXCOVID program in two parallel paths :-

1. Initiation of a Phase 1 study (NOXCOVID-1) in COVID-19 patients in Europe to provide key safety and clinical evidence of proof-of-principle cost-effectively;

2. Continuing discussions with FDA towards gaining Investigational New Drug (IND) approval for an expanded clinical trial in USA.

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

If you are a sophisticated investor as defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

We can alert you to wholesale investment opportunities not available to regular investors.

Please subscribe if you would like to be alerted to these types of opportunities.